

10/025,184


- 2 -

Amendments to the Claims

Please amend Claims 2 and 8. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Canceled)
2. (Currently amended) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer or a salt thereof, said homopolymer characterized by Formula I, Formula II or a combination thereof:



and further characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent wherein the unit dosage form is a tablet.


3. (Previously presented) The pharmaceutical composition of Claim 2 wherein the polymer is crosslinked using epichlorohydrin.

Claims 4-7. (Canceled)

8. (Currently amended) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer or a salt thereof, said homopolymer characterized by Formula I, Formula II or a combination thereof:

10/025,184

- 3 -



and further characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent wherein the unit dosage form is a capsule.

9. (Previously presented) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is in the free base form.
10. (Previously presented) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is a salt or partial salt.
11. (Previously presented) The pharmaceutical composition of Claim 8, wherein the polydiallylamine homopolymer is in the free base form.
12. (Previously presented) The pharmaceutical composition of Claim 8, wherein the polydiallylamine homopolymer is a salt or partial salt.
13. (Previously presented) The pharmaceutical composition of Claim 8, wherein the polymer is crosslinked using epichlorohydrin.
14. (Previously presented) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is water-insoluble.
15. (Previously presented) The pharmaceutical composition of Claim 8, wherein the polydiallylamine homopolymer is water-insoluble.